Literature DB >> 11531318

Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies.

I Malik1, M Hussain, H Yousuf.   

Abstract

OBJECTIVE: To study the frequency of neutropenic febrile patients who present in shock, to evaluate the influence of this presenting feature on response to antibiotic therapy, morbidity, and mortality and to identify discriminating demographic features and clinical characteristics of these individuals.
METHODS: Prospectively collected data on all episodes of fever and neutropenia observed in cancer patients who were hospitalized for parenteral antibiotic therapy.
RESULTS: Five hundred and seventy-six patients were evaluated; 22 (3.8%) presented in shock. This group of individuals was compared with the remainder. Patients presenting in shock were more likely to be older (P< 0.01) and have progressive unresponsive cancer (P< 0.01). They were also more likely to present with septic appearance (P< 0.01), dehydration (P< 0.01), diarrhoea (P< 0.01), altered mental status (P< 0.01) clinical bleeding (P= 0.02) and dyspnoea (P< 0.01). They more often had anaemia (P< 0.01), thrombocytopenia (P= 0.02) and abnormal liver function tests (P< 0.01). Eight of the 22 patients presenting in shock had documented bacteraemia. Non-bacteraemic microbiological infections were observed in three patients. Five patients had clinical evidence of infection and another five were severely dehydrated and volume depleted. One patient had cardiogenic shock. Three patients were managed with monotherapy, 19 received combination antibiotics as initial empirical therapy. Overall outcome of these patients was extremely poor, particularly those with infectious aetiology. Eighteen (82%) patients expired.
CONCLUSION: Neutropenic febrile patients who present in shock have extremely poor outcomes irrespective of type of initial antibiotic therapy. Intense efforts are required to improve their outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11531318     DOI: 10.1053/jinf.2001.0798

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  10 in total

Review 1.  Shock and Early Death in Hematologic Patients with Febrile Neutropenia.

Authors:  Mariana Guarana; Marcio Nucci; Simone A Nouér
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 2.  Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis.

Authors:  Chun-Wei Wu; Jiunn-Yih Wu; Chun-Kuei Chen; Shiau-Ling Huang; Shou-Chien Hsu; Meng-Tse Gabriel Lee; Shy-Shin Chang; Chien-Chang Lee
Journal:  Support Care Cancer       Date:  2015-02-21       Impact factor: 3.603

Review 3.  Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.

Authors:  Bradford R Hirsch; Gary H Lyman
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

4.  Comparison of mortality between nosocomial and community-acquired febrile neutropenia patients treated initially with cefazolin plus tobramycin: retrospective chart review.

Authors:  M Elligsen; S A N Walker; S E Walker; F LePiane; N Lathia; C De'Angelis; A Simor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06       Impact factor: 3.267

5.  How we treat febrile neutropenia in patients receiving cancer chemotherapy.

Authors:  Gary H Lyman; Kenneth V I Rolston
Journal:  J Oncol Pract       Date:  2010-05       Impact factor: 3.840

6.  5-Fluorouracil disrupts skeletal muscle immune cells and impairs skeletal muscle repair and remodeling.

Authors:  Brandon N VanderVeen; Thomas D Cardaci; Sarah S Madero; Sierra J McDonald; Brooke M Bullard; Robert L Price; James A Carson; Daping Fan; E Angela Murphy
Journal:  J Appl Physiol (1985)       Date:  2022-08-25

7.  Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia.

Authors:  Brunna E Alves; Silmara A L Montalvao; Franciso J P Aranha; Tania F G Siegl; Carmino A Souza; Irene Lorand-Metze; Joyce M Annichino-Bizzacchi; Erich V De Paula
Journal:  BMC Infect Dis       Date:  2010-05-28       Impact factor: 3.090

8.  Management of chemotherapy-associated febrile neutropenia.

Authors:  D Cameron
Journal:  Br J Cancer       Date:  2009-09       Impact factor: 7.640

9.  Aetiology of bacteraemia as a risk factor for septic shock at the onset of febrile neutropaenia in adult cancer patients.

Authors:  Regis Goulart Rosa; Luciano Zubaran Goldani
Journal:  Biomed Res Int       Date:  2014-03-20       Impact factor: 3.411

10.  Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.

Authors:  Peter A Fasching; Lothar Häberle; Brigitte Rack; Liang Li; Alexander Hein; Arif B Ekici; Andre Reis; Michael P Lux; Julie M Cunningham; Matthias Ruebner; Gergory Jenkins; Brooke Fridley; Andreas Schneeweiss; Hans Tesch; Werner Lichtenegger; Tanja Fehm; Georg Heinrich; Mahdi Rezai; Matthias W Beckmann; Wolfgang Janni; Richard M Weinshilboum; Liewei Wang
Journal:  Oncotarget       Date:  2017-05-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.